Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Sanofi SA and Teva Pharmaceuticals, a US subsidiary of Teva Pharmaceutical Industries Ltd, on Wednesday announce collaboration to co-develop and co-commercialize asset TEV’574.
Sanofi is a Paris-based pharmaceutical company. Teva Pharmaceutical is also a pharmaceutical company, with headquarters in Tel Aviv.
TEV’574, a novel anti-TL1A therapy, is being developed to treat ulcerative colitis and Crohn’s disease. Ulcerative colitis and Crohn’s disease are two types of inflammatory bowel disease.
As part of the agreement, Teva will receive an upfront payment of €469 million and up to €940 million in development and launch milestones.
Teva will lead commercialization of the product in Europe, Israel and specified other countries, and Sanofi will lead commercialization in North America, Japan, other parts of Asia and the rest of the world.
Initial program results are expected to be available in 2024.
Chief Executive Paul Hudson said: ‘Anti-TL1As are a promising class of therapies, and we believe that TEV’574 could emerge as a best-in-class option for people living with serious gastrointestinal diseases. This collaboration strengthens our commitment to advancing innovative treatment options for inflammatory conditions with a high unmet need and bolsters our goal to be an industry leader in immunology.’
Copyright 2023 Alliance News Ltd. All Rights Reserved.